Enanta Pharmaceuticals(ENTA) - 2023 Q1 - Earnings Call Presentation

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19 • Low frequency of adverse events; most were mild in severity – 1.3%, 6.4%, and 2.6% in the EDP-235 200mg, 400mg and placebo arms Clinical Symptoms – Additional analysis of patients with baseline viral load >5 log showed decline of 0.4 log at day 3 with EDP-235 compared to placebo • Rapid decline in nasal viral RNA observed in all study ar ...